RU2240131C1 - Agent "artrovit" for prophylaxis and treatment of arthritis and arthrosis - Google Patents

Abstract

FIELD: medicine, chemical-pharmaceutical industry, phytotherapy.

SUBSTANCE: invention relates to the development of vegetative-base curative-prophylactic agent used for treatment of arthritis and arthrosis. Agent for prophylaxis and treatment of arthritis and arthrosis comprises the following components taken in equal parts: plantain extract or black elder flower extract, pot-marigold extract, thyme extract or elecampane roots extract, cowberry leaves extract, dandelion roots extract or burdock roots extract, or wild rose extract. Agent can comprise additionally sage extract as an active component, and nettle extract or bur-marigold extract, or violet pensy extract. Agent represents a liquid agent or tablet, or capsule with the content of active components 0.05-1 wt.-%. Agent can comprise sweetening agent and preserving agent additionally. Clinical tests show that agent elicits analgetic and definite anti-inflammatory effect and agent shows effectiveness for treatment of osteoarthrosis being as both in carrying out monotherapy and in complex treatment.

EFFECT: valuable medicinal properties of agent.

6 cl, 2 tbl

Description

The invention relates to the parapharmaceutical industry, producing drugs for therapeutic and prophylactic purposes based on components of plant origin, and can be used for the prevention and treatment of rheumatic diseases or as a biologically active additive (BAA).

The treatment of joint diseases is a lengthy process associated with the use of a wide range of pharmacological drugs. Herbal remedies used to treat arthritis and arthrosis should contain a balanced complex of biologically active substances that have a versatile therapeutic effect on the patient's body (anti-inflammatory, antibacterial, restorative, analgesic, diuretic, diaphoretic, antiallergic, etc.).

Known biologically active additive, including as active components, in particular, calendula, plantain, nettle (patent RU 2122424, 1998). Supplements have a restorative effect on the patient's body.

However, there is no indication of the possibility of using the known dietary supplement for the treatment of joint diseases.

Also known is a tool (dietary supplement), among the components of which are burdock, elecampane, sage and ascorbic acid (patent RU 2191591, 2002).

A disadvantage of the known means is a narrow spectrum of action, allowing its use only for some rheumatic diseases.

The tool according to the invention allows to expand the spectrum of action of the drug and use it for the prevention and treatment of arthritis and arthrosis.

The composition of the product in equal shares includes plant extracts containing the active components:

plantain extract or elderberry flower black,

calendula extract

thyme or elecampane root extract,

lingonberry leaf extract,

extract of dandelion root, or burdock, or rose hip.

The tool may additionally contain as an active component

sage extract;

nettle extract, or a string, or tricolor violets.

Each of the components (extracts) that make up the product called “Arthrovit” by the authors is a well-known dosage form manufactured by the pharmaceutical industry (see, for example, Sokolov. S.Ya., Zamotaev I.P. Handbook of medicinal plants. 2nd ed., Moscow: Medicine, 1988). So, obtaining the extract of plantain in the form of a decoction of leaves (Decoctum folii Plantaginis) is described on page 163 of the specified directory; black elderberry flower extract in the form of infusion (Infusumflorum Sambuci nigrae) - on page 121; Calendula Extract (Tinctura Calendulae) - on pages 154-155; thyme extract (Infusum herbae Thymi vulgaris) - on page 216; extract of elecampane root (Decoctum rhizoma et radix Inulae helenii) - on page 145, etc.

The tool is obtained by mixing these components. It can be used in liquid form (drops under the tongue) with a content of 0.05-1 wt.% Of the active components or may be a tablet or capsule containing 0.1-2 wt.% Of the active components with pharmaceutically acceptable carriers.

The tool helps to normalize metabolism, regenerate cartilage, microcirculation in the joints, has anti-inflammatory, anti-allergic, anti-sclerotic, analgesic, hypoglycemic effects, includes trace elements and vitamins.

Extracts of plantain or elderberry flowers have anti-inflammatory and antimicrobial properties. As part of the proposed tool, these components can be used interchangeably. Calendula extract exhibits anti-allergic and wound healing effects. Calendula also calms the nervous system, lowers blood pressure, strengthens heart activity and slows heart rate. Extracts of thyme or elecampane root have anti-inflammatory and general strengthening effect. Lingonberry leaf extract helps regulate salt metabolism in the body, exhibits an antiseptic effect. Extracts of the roots of dandelion, burdock or dogrose, interchangeable in the composition of the proposed funds, have anti-sclerotic and choleretic properties. With a joint action, all of the listed components of the drug also normalize the metabolism, have immunomodulating, diuretic and diaphoretic effects.

In addition, the addition of sage extract can enhance the anti-inflammatory and antimicrobial effect of the “Arthrovit” remedy. Any of the extracts of nettle, string or tricolor violet can further contribute to the normalization of metabolism. In the composition of the finished form, the product, as a rule, additionally contains a sweetener and preservative. As a sweetener, in particular, licorice root, which also has anti-inflammatory and diuretic properties, can be used. Sodium benzoate, ascorbic acid or citric acid are usually used as a preservative.

The data on the practical testing of the product are presented below for a liquid form containing a mixture of plantain extracts, calendula flowers, thyme, dandelion root, lingonberry leaves, sage and nettle. To prepare 100 g of Arthrovit, 1 g of each of the seven extracts listed was used, 0.5 g of preservative and sweetener in total, the rest was water. The total content of active components was 0.65 wt.%.

A clinical study of the efficacy and tolerability of the drug was carried out on 20 patients with osteoarthrosis (OA) with damage to the knee (gonarthrosis) and hip joints (coxarthrosis). Evaluation of the effectiveness and tolerability of “Artrovita” was carried out on a special thematic map, which included general information about the patient, the duration of the disease, the presence of concomitant diseases, previous treatment.

The following criteria were evaluated (before, after 2 weeks, after 1 month, at the end of treatment): pain at rest (mm according to YOUR), pain during movement (mm according to YOUR), pain during palpation (mm according to YOUR), signs of synovitis (in points), drug tolerance and side effects. Assessment of treatment results was carried out separately by the doctor and the patient according to such gradations as significant improvement, improvement, no effect and worsening.

Arthrovit was prescribed to 20 patients with osteoarthritis at a dose of 15-20 drops 2 times a day (under the tongue) in the morning and evening.

Table 1 shows the clinical characteristics of 20 patients with osteoarthrosis. Among the observed patients predominated with a predominant lesion of the knee joints - 14 patients, with a combination of lesions of the knee and hip joints - 6 patients. 13 patients had signs of reactive synovitis. Of the concomitant diseases in the analyzed group, the following were noted: arterial hypertension in 8 patients (40%); coronary heart disease in 3 patients (15%); peptic ulcer in 4 patients (20%); chronic gastritis in 3 patients (15%); chronic pancreatitis in 2 patients (10%); chronic cholecystitis in 1 patient (5%); diabetes mellitus in 1 patient (5%).

13 patients took only the test supplement, 2 patients took the structure for a long time, 5 patients received non-steroidal anti-inflammatory drugs (Ortofen, Ibuprofen, Nise). The main group of concomitant therapy was the antihypertensive drugs enap, arifon, preductal, atenolol.

The results of the therapy and the dynamics of the evaluated parameters are presented in table 2.

As can be seen from table 2, marked dynamics of clinical parameters were noted: pain syndrome significantly decreased: pain at rest from 37.2 ± 25.33 to 22.85 ± 22.7 (p = 0.005), pain during movement from 59 ± 18, 76 to 41.7 ± 21.2 (p = 0.004), pain on palpation from 41.35 ± 17.69 to 29.5 ± 20.79 (p = 0.035). Signs of a mild reactive synovitis disappeared in 5 patients and in one with a mild reactive synovitis.

According to the doctor, a significant improvement in the articular syndrome was detected in 2 patients (10%) and improvement in 15 patients (75%). Lack of effectiveness was registered in 3 patients (15%), and in 2 patients with OA with a far advanced stage IV disease, when the traditional therapy of NSAIDs and the disease with modifying agents (structure) are also not effective enough. None of the patients showed increased pain in the joints. Two patients also significantly reduced morning stiffness in the joints, in one patient tenosynovitis was completely stopped.

According to the patients themselves, significant improvement was observed in 3 (15%), improvement in 13 (65%) and lack of effect in 4 patients (20%).

Simultaneously with the positive dynamics of the articular syndrome in 8 patients (40%), an improvement in general condition was noted, fatigue decreased, cheerfulness appeared, edema was reduced, and gastrointestinal tract function improved. There was no deterioration in the course of concomitant diseases both on the part of the cardiovascular system and the gastrointestinal tract.

The use of Arthrovit allowed one patient to refuse to take ibuprofen within the last two weeks, the second patient reduced the dose of orthophene by 50 mg and the third patient reduced the dose of Nize from 100 to 50 mg.

In 18 patients, excellent and good tolerability of the drug was recorded. Drug withdrawal due to side effects was not noted.

Based on the results obtained, it can be stated that Arthrovit has an analgesic and certain anti-inflammatory effect and is quite effective for the treatment of osteoarthritis both as monotherapy and in complex treatment.

Good tolerance and the absence of serious side effects makes it possible to recommend Arthrovit to patients with osteoarthritis who have NSAID-induced gastropathy and other undesirable effects caused by NSAIDs, as well as patients with OA suffering from concomitant diseases.

Claims (6)

1. An agent for the prevention and treatment of arthritis and arthrosis, characterized in that it contains the following plant active components in equal proportions: extract of plantain or elderberry flower, calendula extract, thyme or elecampane root extract, lingonberry leaf extract, dandelion root extract, or burdock, or rose hips. 2. The tool according to claim 1, characterized in that it further comprises, as an active component, sage extract and nettle extract, or a string, or tricolor violet. 3. The tool according to claim 1 or 2, characterized in that it is a liquid tool containing 0.05-1 wt.% Active components. 4. The tool according to claim 1 or 2, characterized in that it is a tablet or capsule containing 0.1-2 wt.% Of the active components. 5. The tool according to claim 3 or 4, characterized in that it further comprises a sweetener and preservative. 6. The tool according to claim 5, characterized in that as a sweetener contains licorice root, and as a preservative contains sodium benzoate, or ascorbic acid, or citric acid.